New drug BL-B01D1 tested in tiny early trial for tough cancers
NCT ID NCT05393427
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called BL-B01D1 in people with advanced urinary or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and get a first look at whether it might shrink tumors. Only 4 participants are enrolled, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for advanced urinary and other solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 4 participants, so it is primarily checking safety and dosing. It is too small and early to know if the drug will be effective or have manageable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OTHER SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Peking University First Hospital
Beijing, Beijing Municipality, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China